PHOQUS COMPLETES CHRONOCORT CLINICAL STUDY

Phoqus, has announced that it has completed Phase I of its clinical study on Chronocort, the first circadian endocrine treatment for adrenal insufficiency that current steroid therapies for this condition do not mimic.

Phoqus now plans to license the product, later in 2006, to a marketing partner to complete the development and launch the product. Chronocort already has orphan medicinal product designation in the EU.

The Phase I trial involved volunteers who had their natural cortisol hormone production suppressed and were then dosed with Chronocort.